iPSC-CAR-NK therapy (HebeCell/Jacobio)

N/A

Report date: 2025/01/26 15:39:32

Base Information

Drug NameiPSC-CAR-NK therapy (HebeCell/Jacobio)
Drug Alias NameCAR NK-cell therapy (HebeCell/Jacobio)allogeneic iPSC-derived CAR NK-cell therapy (HebeCell/Jacobio)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionNatural killer cells stimulantsImmunostimulants
TargetsUpdating
Therapy Area/IndicationsAutoimmune DiseasesNeoplasmsVirus Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesHebeCell Corp
China Registration ClassN/A

Develop Information

Active CompaniesHebeCell Corp
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesNeoplasmsVirus Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A